Limits...
Interleukin 9-induced in vivo expansion of the B-1 lymphocyte population.

Vink A, Warnier G, Brombacher F, Renauld JC - J. Exp. Med. (1999)

Bottom Line: In normal mice, the IL-9 receptor was found to be expressed by CD5(+) as well as CD5(-) B-1 cells, and repeated injections of IL-9 resulted in accumulation of B-1 cells in the peritoneal cavity, as observed in transgenic animals.Unlike other mouse models, such as IL-5 transgenic mice, in which expansion of the B-1 population is associated with high levels of autoantibodies, IL-9 did not stimulate the production of autoantibodies in vivo, and most of the expanded cells were found to belong to the B-1b subset (IgM+Mac-1(+)CD5(-)).In addition, we found that these IL-9-expanded B-1b cells do not share the well-documented antibromelain-treated red blood cell specificity of CD5(+) B-1a cells.

View Article: PubMed Central - PubMed

Affiliation: Ludwig Institute for Cancer Research, Experimental Medicine Unit, University of Louvain, B-1200 Brussels, Belgium. vink@licr.ucl.ac.be

ABSTRACT
The activity of interleukin (IL)-9 on B cells was analyzed in vivo using transgenic mice that constitutively express this cytokine. These mice show an increase in both baseline and antigen-specific immunoglobulin concentrations for all isotypes tested. Analysis of B cell populations showed a specific expansion of Mac-1(+) B-1 cells in the peritoneal and pleuropericardial cavities, and in the blood of IL-9 transgenic mice. In normal mice, the IL-9 receptor was found to be expressed by CD5(+) as well as CD5(-) B-1 cells, and repeated injections of IL-9 resulted in accumulation of B-1 cells in the peritoneal cavity, as observed in transgenic animals. Unlike other mouse models, such as IL-5 transgenic mice, in which expansion of the B-1 population is associated with high levels of autoantibodies, IL-9 did not stimulate the production of autoantibodies in vivo, and most of the expanded cells were found to belong to the B-1b subset (IgM+Mac-1(+)CD5(-)). In addition, we found that these IL-9-expanded B-1b cells do not share the well-documented antibromelain-treated red blood cell specificity of CD5(+) B-1a cells. The increase of antigen-specific antibody concentration in immunized mice suggests that these B-1 cells are directly or indirectly involved in antibody responses in IL-9 transgenic mice.

Show MeSH

Related in: MedlinePlus

Kinetics of accumulation of peritoneal cells in IL-9 transgenic (Tg5 and Tg54) and FVB mice. Peritoneal cells were counted from  groups of 5 mice of 3, 6, 9, and 12 wk of age and 10 mice of 24 and  48 wk of age. Results are expressed as cell numbers per mouse ± SD.  The difference between transgenic and control mice was statistically significant for all ages tested (Mann-Whitney test).
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC2193070&req=5

Figure 4: Kinetics of accumulation of peritoneal cells in IL-9 transgenic (Tg5 and Tg54) and FVB mice. Peritoneal cells were counted from groups of 5 mice of 3, 6, 9, and 12 wk of age and 10 mice of 24 and 48 wk of age. Results are expressed as cell numbers per mouse ± SD. The difference between transgenic and control mice was statistically significant for all ages tested (Mann-Whitney test).

Mentions: Fig. 4 shows the kinetics of accumulation of peritoneal cells in two IL-9 transgenic lines (Tg5 and Tg54). At 3 wk of age, there was already a significant difference between the number of peritoneal cells found in the peritoneal cavity of transgenic mice compared with control mice (P < 0.008, Mann-Whitney test). This difference reached five- to sevenfold after 6–12 wk, and peritoneal numbers remained stable at this level throughout the life of the individuals. Animals of >18 mo presented a similarly enlarged cell population as younger individuals (data not shown). In aging FVB control mice, peritoneal cell numbers increased slightly compared with young individuals.


Interleukin 9-induced in vivo expansion of the B-1 lymphocyte population.

Vink A, Warnier G, Brombacher F, Renauld JC - J. Exp. Med. (1999)

Kinetics of accumulation of peritoneal cells in IL-9 transgenic (Tg5 and Tg54) and FVB mice. Peritoneal cells were counted from  groups of 5 mice of 3, 6, 9, and 12 wk of age and 10 mice of 24 and  48 wk of age. Results are expressed as cell numbers per mouse ± SD.  The difference between transgenic and control mice was statistically significant for all ages tested (Mann-Whitney test).
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC2193070&req=5

Figure 4: Kinetics of accumulation of peritoneal cells in IL-9 transgenic (Tg5 and Tg54) and FVB mice. Peritoneal cells were counted from groups of 5 mice of 3, 6, 9, and 12 wk of age and 10 mice of 24 and 48 wk of age. Results are expressed as cell numbers per mouse ± SD. The difference between transgenic and control mice was statistically significant for all ages tested (Mann-Whitney test).
Mentions: Fig. 4 shows the kinetics of accumulation of peritoneal cells in two IL-9 transgenic lines (Tg5 and Tg54). At 3 wk of age, there was already a significant difference between the number of peritoneal cells found in the peritoneal cavity of transgenic mice compared with control mice (P < 0.008, Mann-Whitney test). This difference reached five- to sevenfold after 6–12 wk, and peritoneal numbers remained stable at this level throughout the life of the individuals. Animals of >18 mo presented a similarly enlarged cell population as younger individuals (data not shown). In aging FVB control mice, peritoneal cell numbers increased slightly compared with young individuals.

Bottom Line: In normal mice, the IL-9 receptor was found to be expressed by CD5(+) as well as CD5(-) B-1 cells, and repeated injections of IL-9 resulted in accumulation of B-1 cells in the peritoneal cavity, as observed in transgenic animals.Unlike other mouse models, such as IL-5 transgenic mice, in which expansion of the B-1 population is associated with high levels of autoantibodies, IL-9 did not stimulate the production of autoantibodies in vivo, and most of the expanded cells were found to belong to the B-1b subset (IgM+Mac-1(+)CD5(-)).In addition, we found that these IL-9-expanded B-1b cells do not share the well-documented antibromelain-treated red blood cell specificity of CD5(+) B-1a cells.

View Article: PubMed Central - PubMed

Affiliation: Ludwig Institute for Cancer Research, Experimental Medicine Unit, University of Louvain, B-1200 Brussels, Belgium. vink@licr.ucl.ac.be

ABSTRACT
The activity of interleukin (IL)-9 on B cells was analyzed in vivo using transgenic mice that constitutively express this cytokine. These mice show an increase in both baseline and antigen-specific immunoglobulin concentrations for all isotypes tested. Analysis of B cell populations showed a specific expansion of Mac-1(+) B-1 cells in the peritoneal and pleuropericardial cavities, and in the blood of IL-9 transgenic mice. In normal mice, the IL-9 receptor was found to be expressed by CD5(+) as well as CD5(-) B-1 cells, and repeated injections of IL-9 resulted in accumulation of B-1 cells in the peritoneal cavity, as observed in transgenic animals. Unlike other mouse models, such as IL-5 transgenic mice, in which expansion of the B-1 population is associated with high levels of autoantibodies, IL-9 did not stimulate the production of autoantibodies in vivo, and most of the expanded cells were found to belong to the B-1b subset (IgM+Mac-1(+)CD5(-)). In addition, we found that these IL-9-expanded B-1b cells do not share the well-documented antibromelain-treated red blood cell specificity of CD5(+) B-1a cells. The increase of antigen-specific antibody concentration in immunized mice suggests that these B-1 cells are directly or indirectly involved in antibody responses in IL-9 transgenic mice.

Show MeSH
Related in: MedlinePlus